drugset / Trial / NCT02889562

Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation

NCT02889562

Phase 2/3 Completed 56 enrolled Sanford Health Bristol-Myers Squibb · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

In this open-label, prospective, randomized pilot study, patients who develop atrial fibrillation after isolated coronary artery bypass grafting surgery will be identified. Patients with persistent atrial fibrillation (\>12 hours) or recurrent sustained atrial fibrillation (\>2 episodes of atrial fibrillation lasting longer than 30 minutes) will be candidates for inclusion. Upon meeting study inclusion and exclusion criteria, and after informed consent, patients will be randomized to either the standard of care (warfarin per protocol) or apixaban arms of the trial. Routine postoperative care after CABG will occur in both groups. Upon discharge, anticoagulation in both groups will be managed by the anticoagulation clinic. Patients will be followed for 30 days after surgery.

Timeline

Start
2016-09
Primary completion
2019-05-11
Completion
2019-05-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Apixaban Small molecule 5 mg Oral
Comparator Warfarin Small molecule 0.5 mg Oral
Comparator Warfarin Small molecule 15 mg Oral